ASP Isotopes Inc. is a NASDAQ-listed (ASPI) advanced materials company that enriches stable isotopes using two proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment. It operates enrichment facilities in Pretoria, South Africa, supplying isotopes including Carbon-14, Molybdenum-100, Zinc-68, Nickel-64, Ytterbium-176, highly enriched Silicon-28, and depleted Germanium-73 to nuclear medicine and semiconductor customers, and holds a 51% majority stake in South African radiopharmaceutical operator PET Labs.
Through its subsidiary Quantum Leap Energy, the company is developing enriched nuclear fuels such as HALEU, LEU+, and enriched lithium for next-generation reactors, and it completed the acquisition of South African helium and LNG producer Renergen Limited, whose Virginia Gas Project joins the group portfolio. The company is headquartered in Dallas, Texas.
ASP Isotopes enriches stable isotopes for medical, semiconductor, and nuclear energy customers with Aerodynamic Separation Process and Quantum Enrichment technologies.
Medical Isotopes is ASP Isotopes' enriched isotope line for nuclear medicine, supplying Molybdenum-100, Ytterbium-176, Zinc-68, Nickel-64, and Carbon-14 precursors.